



Artery Research

ISSN (Online): 1876-4401

ISSN (Print): 1872-9312

Journal Home Page: <https://www.atlantis-press.com/journals/artres>

Gender and endothelial progenitor cell number in middle-aged adults

Brian L. Stauffer, Owen J. MacEneaney, Erich J. Kushner, Jennifer N. Cech, Jared J. Greiner, Christian M. Westby, Christopher A. DeSouza

To cite this article: Brian L. Stauffer, Owen J. MacEneaney, Erich J. Kushner, Jennifer N. Cech, Jared J. Greiner, Christian M. Westby, Christopher A. DeSouza (2008) Gender and endothelial progenitor cell number in middle-aged adults, Artery Research 2:4, 156–160, DOI: <https://doi.org/10.1016/j.artres.2008.10.001>

To link to this article: <https://doi.org/10.1016/j.artres.2008.10.001>

Published online: 14 December 2019



available at www.sciencedirect.com



journal homepage: www.elsevier.com/locate/artres



Gender and endothelial progenitor cell number in middle-aged adults

Brian L. Stauffer^{a,b,c,*}, Owen J. MacEneaney^a, Erich J. Kushner^a, Jennifer N. Cech^a, Jared J. Greiner^a, Christian M. Westby^a, Christopher A. DeSouza^{a,b}

^a Integrative Vascular Biology Laboratory, Department of Integrative Physiology, University of Colorado, Boulder, CO, USA

^b Department of Medicine, University of Colorado at Denver and the Health Sciences Center, Aurora, CO, USA

^c Department of Medicine, Division of Cardiology, Denver Health and Hospital Authority, Denver, CO, USA

Received 13 August 2008; received in revised form 8 October 2008; accepted 9 October 2008

Available online 13 November 2008

KEYWORDS

Endothelial progenitor cells;
Gender;
Endothelium

Summary *Background:* Between the ages of 45 and 65 years, the prevalence of cardiovascular disease is significantly lower in women compared with men. Circulating bone marrow-derived endothelial progenitor cells (EPCs) play an important role in vascular repair. Reduced EPC number is predictive of more cardiovascular events. It is currently unknown whether there is a sex-difference in EPC number in middle-aged adults.

Objective: We tested the hypothesis that circulating EPC number is higher in middle-aged women than men.

Methods: Peripheral blood samples were collected from 58 sedentary adults, 29 men (57 ± 1 years) and 29 women (58 ± 1 years). Mononuclear cells were isolated and fluorescence-activated cell sorting (FACS) analysis of cells negative for CD45 was performed for those positive for CD34, and triple positive for CD34, VEGFR-2, and CD133 according to the recommendations of the International Society for Hematotherapy and Graft Engineering.

Results: The number of CD45⁻/CD34⁺ and CD45⁻/CD34⁺/VEGFR-2⁺/CD133⁺ was not significantly different between women and men ($0.055 \pm 0.006\%$ vs $0.069 \pm 0.008\%$ and $0.0013 \pm 0.0003\%$ vs $0.0018 \pm 0.0004\%$, respectively).

Conclusions: These results demonstrate no sex-difference in EPC number in middle-age adults. Therefore, it is unlikely that differences in EPC number contribute to the gender-related differences in the prevalence of cardiovascular events in this population.

© 2008 Association for Research into Arterial Structure and Physiology. Published by Elsevier B.V. All rights reserved.

* Corresponding author. Integrative Vascular Biology Laboratory, Department of Integrative Physiology, University of Colorado at Boulder, UCB 436, Boulder, CO 80309, USA. Tel.: +1 303 724 5440; fax: +1 303 724 5450.

E-mail address: brian.stauffer@ucdenver.edu (B.L. Stauffer).

Introduction

Cardiovascular disease remains the leading cause of death in both men and women. However, between the ages of 45 and 65, men have a significantly higher risk of myocardial infarction and stroke than women in the absence of a gender-related difference in the prevalence of traditional cardiovascular disease risk factors such as hypertension, tobacco use, obesity, diabetes, sedentary behavior and hyperlipidemia.¹ It is now apparent that vascular endothelial dysfunction is a critical prelude to all major cardiovascular diseases, including myocardial infarction and stroke. Endothelial dysfunction occurs when vascular repair mechanisms are unable to keep pace with on-going vascular injury (i.e. from pathologic conditions such as hypertension, hyperlipidemia, etc.).²

Bone marrow-derived endothelial progenitor cells (EPCs) play an integral role in the maintenance of vascular health. EPC-mediated vascular repair is associated with normalization of endothelial function and restoration of blood flow at the site of injury.³ Clinical interest in circulating EPCs has increased in the wake of recent studies indicating that reductions in EPC levels are an excellent predictor of cardiovascular events^{4–7} and a surrogate marker for vascular function.⁴ Moreover, increases in circulating EPC number in response to interventions such as exercise, smoking cessation and statin therapy are thought to contribute to their cardiovascular benefit.^{8,9}

While mechanisms underlying the observed gender difference in clinical cardiovascular events in middle-aged adults are not fully elucidated, we recently demonstrated important gender differences in contributors to vascular health. Middle-aged men demonstrate lower endothelial tissue-type plasminogen activator (t-PA) release compared to women.¹⁰ Impairment in the capacity of the endothelium to release t-PA has been directly linked to increased atheromatous burden and increased coronary atherothrombosis.¹¹ Given the important link between circulating EPCs, endothelial function and vascular disease it is possible that differences in EPC number may also contribute to the gender-related difference in cardiovascular events in middle-aged adults.

It is currently unknown whether circulating EPC number differs between middle-aged women and men. Lower circulating levels of EPCs may contribute to the higher incidence of cardiovascular morbidity and mortality in middle-aged men compared with women. Accordingly, we tested the hypothesis that the number of circulating EPCs is lower in middle-aged men compared with women.

Methods

Subjects

Peripheral blood samples were collected from 58 healthy, sedentary middle-aged adults, 29 men and 29 women. All subjects were non-obese (body mass index ≤ 30 kg/m²), normotensive, nonsmokers, nonmedicated, and free of overt cardiovascular, metabolic, and hematologic diseases as assessed by medical history, electrocardiograms

obtained during exercise and at rest, and fasting blood chemistries. The women were ≥ 1 year postmenopausal (range 1–25 years) and had never taken or discontinued use of hormone replacement therapy ≥ 1 year before the start of the study. Framingham risk score was calculated as previously described.¹² All subjects provided written informed consent and the study protocol conforms to the ethical guidelines of the 1975 Declaration of Helsinki as reflected in a priori approval by the University of Colorado at Boulder human research committee.

EPC isolation and number

Circulating EPC number was determined by fluorescence-activated cell sorting (FACS) analysis following guidelines recommended by the International Society for Hematotherapy and Graft Engineering.¹³ Briefly, peripheral blood mononuclear cells (PBMCs) were isolated by Ficoll density-gradient centrifugation (Histopaque 1077, Sigma, St. Louis, Missouri), washed, and resuspended in growth medium (Medium 199, Gibco, Grand Island, New York), supplemented with 20% fetal calf serum, penicillin (100 U/ml), and streptomycin (100 mg/ml). Endothelial phenotype of these cells was confirmed in a subset of samples by immunofluorescent staining for the uptake of Dil-ac-LDL (Biomedical Technologies Inc., Stoughton, MA, USA) and expression of von Willebrand factor (Dako, Glostrup, Denmark), VE-cadherin, CD31 and VEGFR-2 (Invitrogen, Carlsbad, CA, USA).

Cells (2.0×10^6) were incubated at 4 °C for 30 min with antibodies against PC7-conjugated CD45, FITC-conjugated CD34, PE-conjugated VEGFR-2, and APC-conjugated CD133. Nonviable cells were excluded with propidium iodide. Samples were gated first for lack of expression of CD45 then analyzed for those events positive for CD34 and triple positive for CD34, VEGFR-2 (also previously identified as KDR or Flk-1) and CD133^{7,14,15} and presented as percent of total viable cells. All samples were analyzed using an FC500 flow cytometer (Beckman Coulter, Fullerton CA) and the data analyzed using CXP software.

Recent data demonstrate that CD34⁺ cells not expressing the common leukocyte antigen (CD45⁻) were found to yield endothelial colony-forming cells, while those expressing CD45 demonstrated hematopoietic progenitor properties.¹⁶ Therefore, in accordance with previous studies,^{14,17,18} we identified putative EPCs as those without expression of CD45 while still expressing the additional markers as outlined above.

Statistical analysis

Group differences in subject characteristics and FACS data were determined by analysis of variance (ANOVA). Relations between variables of interest were assessed by Pearson's correlation coefficient and linear regression analysis. Based on the magnitude of the differences that were observed in EPC number between groups, post hoc power calculations indicated that the sample size was sufficient to detect significant main effects. Data are reported as mean \pm SEM. Statistical significance was set at $P < 0.05$.

Results

Subject characteristics

Selected subject characteristics are presented Table 1. Although none of the subjects were obese, the men demonstrated significantly higher body mass and waist circumference and lower percent body fat compared with the women. Other than high-density lipoprotein cholesterol, there were no significant gender-related differences in metabolic or hematologic variables. There were no differences in Framingham risk score between men and women, but the estimated 10-year coronary heart disease risk was significantly higher in men than in women. We observed no relation between risk score or estimated risk and EPC number.

EPC number

Mononuclear cells were first gated for CD45⁻ to exclude leukocytes and decrease the likelihood of false-positive EPC identification. To discover whether the overall number of these hematopoietic precursor cells was different between men and women the number of CD34⁺ cells was determined. Surprisingly, there was no significant difference in CD45⁻/CD34⁺ hematopoietic precursor cells between middle-aged women and men ($0.055 \pm 0.006\%$ vs $0.069 \pm 0.008\%$, Fig. 1a). In addition, we observed no significant gender-related difference in circulating putative EPCs defined as CD45⁻/CD34⁺/VEGFR-2⁺/CD133⁺ cells. The percentage of cells staining triple positive for CD34, VEGFR-2 and CD133 was comparable between middle-aged women and men ($0.0013 \pm 0.0003\%$ vs $0.0018 \pm 0.0004\%$, $P = 0.40$, Fig. 1b).

Table 1 Selected subject characteristics.

Variable	Men (n = 29)	Women (n = 29)
Age (year)	57 ± 1	58 ± 1
Years postmenopausal (year)	—	8 ± 1
Body mass (kg)	84.9 ± 2.3	70.4 ± 2.7*
Body fat (%)	27.8 ± 1.3	38.6 ± 1.3*
Body mass index (kg/m ²)	27.1 ± 0.7	26.0 ± 0.9
Waist circumference (cm)	97.3 ± 1.8	83.6 ± 2.8*
Systolic blood pressure (mmHg)	125 ± 2	120 ± 2
Diastolic blood pressure (mmHg)	77 ± 1	73 ± 1*
Total cholesterol (mmol/L)	5.1 ± 0.1	5.4 ± 0.1
HDL cholesterol (mmol/L)	1.1 ± 0.1	1.7 ± 0.1*
LDL cholesterol (mmol/L)	3.3 ± 0.1	3.3 ± 0.2
Triglycerides (mmol/L)	1.4 ± 0.1	1.2 ± 0.1
Glucose (mmol/L)	5.2 ± 0.1	5.1 ± 0.1
Insulin (pmol/L)	44.4 ± 5.1	42.0 ± 5.1
WBC (1000/μL)	5.2 ± 0.2	5.1 ± 0.2
Mononuclear cells (%)	40.5 ± 1.2	42.2 ± 1.4
Framingham risk score	4.8 ± 0.4	4.5 ± 0.5
Estimated 10-year CHD risk (%)	9.7 ± 0.9	4.9 ± 0.5*

Values are mean ± SEM. HDL, high-density lipoprotein; LDL, low-density lipoprotein; WBC, White Blood Cell Count; CHD, coronary heart disease; * $P < 0.05$ vs men.

Discussion

The novel finding of the present study is that EPC number is not different between middle-aged women and men. Although circulating EPC number is predictive of cardiovascular morbidity and mortality in a number of clinical populations,^{4,5,19} our study suggests that EPC number may not contribute to differences in the cardiovascular event rate between middle-aged men and women. Moreover, it is unlikely that differences in EPC number contribute to the previously documented gender difference in endothelial function.¹⁰ To our knowledge, this is the first study to investigate gender differences in the number of circulating CD45⁻/CD34⁺/VEGFR-2⁺/CD133⁺ cells in healthy adults.

Recently Fadini et al. investigated the influence of gender and estrogen on CD34⁺/VEGFR-2⁺/CD133⁺ cell number.²⁰ While they did not demonstrate any gender difference in their cell population, the expression of CD45, a hematopoietic lineage-specific antigen, was not evaluated. Case et al. demonstrated that CD45 expression was an effective measure to differentiate hematopoietic progenitors from endothelial progenitors,¹⁶ a critical distinction when evaluating the vascular progenitor cell. Thus, while Fadini et al. demonstrated no gender difference in a heterogeneous progenitor population containing both hematopoietic and endothelial precursors, their results cannot exclude the possibility of a gender difference




Figure 1 Percentage of CD45⁻/CD34⁺ (panel A) and CD45⁻/CD34⁺/VEGFR-2⁺/CD133⁺ (panel B) cells in middle-aged men and women.

specifically in the endothelial precursor population.¹⁶ Importantly, it is the cells with endothelial lineage that have been associated with cardiovascular outcomes. The findings of the current study demonstrate no gender difference in a specific EPC population.

Cell surface antigens identify various stages of progenitor cells. CD34 is expressed by all hematopoietic stem cells and is lost as hematopoietic cells differentiate.²¹ CD34⁺ cells are involved in a number of cardiovascular processes. For example, in the myocardium they home to sites of ischemia, enhance neovascularization, and contribute to improved cardiac function.²² Indeed, intramyocardial transplantation of CD34⁺ cells into rats with myocardial infarction has been shown to improve capillary density, fractional shortening and regional contractility.²³ The number of CD34⁺ cells is highly susceptible to cardiovascular risk factors. For instance, CD34⁺ cells are diminished with cigarette smoking, increase with smoking cessation, and decline after subjects resume smoking.¹⁴ A seminal finding of the present study is that gender does not appear to affect circulating CD34⁺ cells. We observed similar numbers of CD34-positive cells in healthy middle-aged, non-obese women and men.

While there is some debate currently in the literature regarding which antigenic profile best identifies progenitor cells with the potential to repair the endothelium,²⁴ triple positive cells identified by the dual expression of CD133, a surface antigen that identifies more immature progenitor cells than CD34 alone, and VEGFR-2, an indicator of early endothelial differentiation, in the CD45⁻/CD34⁺ population are generally accepted as being progenitors of endothelial lineage.^{16,25} The number of circulating CD45⁻/CD34⁺/VEGFR-2⁺/CD133⁺ cells has been shown to be 50% lower in patients with coronary artery disease or Eisenmenger syndrome and 70% lower in individuals who smoke cigarettes, respectively.^{7,14,18} Moreover, these cells are inversely related and independently predictive of carotid intimal medial thickness, an indicator of early subclinical atherosclerosis.²⁶ Both single (CD45⁻/CD34⁺) and triple positive (CD45⁻/CD34⁺/VEGFR-2⁺/CD133⁺) cells are mobilized following myocardial infarction, presumably to assist with myocardial repair and vascular regeneration.¹⁷ Importantly, a reduction in EPCs that express the VEGFR-2 antigen predicts future cardiovascular events⁵ and death from cardiovascular causes.⁶

One important limitation of the current study is that only EPC number demonstrated by FACS analysis was evaluated. It is becoming more evident in the literature that EPC function *ex vivo* is an independent marker of vascular health. Thus, differences in EPC functional characteristics may contribute to differences in cardiovascular events amongst middle-aged men and women. Indeed, we have previously demonstrated a significant gender-related difference in two aspects of EPC function, colony-forming capacity and migration, which have been linked to cardiovascular risk.²⁷ Taken together, these findings suggest that greater EPC function, but not number, may contribute to the lower cardiovascular risk in middle-aged women compared to men.

In conclusion, it is well established that impairment of the vascular endothelium is an important precursor to atherosclerosis and cardiovascular events. Endothelial

dysfunction occurs when repeated endothelial damage, such as from traditional cardiovascular risk factors, overwhelms the endogenous vascular repair mechanisms. We previously demonstrated that middle-aged women have higher endothelial t-PA production compared with men, indicating endothelial dysfunction in men corresponding to the age of gender-discordance in cardiovascular event rates. There is increasing evidence that EPCs play a pivotal role in vascular repair and endothelial replacement. Given the body of literature documenting the relation between EPCs and clinical cardiovascular events, we were surprised to find no gender-dependent difference in EPC number in middle-aged adults. In spite of the predictive value of EPC number in other populations, there was no difference in EPC number between men and women in the age range where there is a substantial gender difference in the prevalence of cardiovascular events. Therefore, a difference in EPC number does not appear to be a contributing factor to the gender-related disparity in the cardiovascular event rate in the middle-aged adult population.

Acknowledgements

This study was supported by awards HL080212, HL076434, HL077450 and MO1 RR00051 from the National Institutes of Health, Bethesda, Maryland and award 0555678Z from the American Heart Association, Dallas, Texas. We thank all the subjects who participated in the study and Yoli Casas, MS for technical assistance.

References

1. Thom T, Haase N, Rosamond W, Howard VJ, Rumsfeld J, Manolio T, et al. Heart disease and stroke statistics – 2006 update: a report from the American Heart Association statistics committee and stroke statistics subcommittee. *Circulation* 2006;113(6):e85–151.
2. Dzau VJ, Gneccchi M, Pachori AS, Morello F, Melo LG. Therapeutic potential of endothelial progenitor cells in cardiovascular diseases. *Hypertension* 2005;46(1):7–18.
3. Fujiyama S, Amano K, Uehira K, Yoshida M, Nishiwaki Y, Nozawa Y, et al. Bone marrow monocyte lineage cells adhere on injured endothelium in a monocyte chemoattractant protein-1-dependent manner and accelerate reendothelialization as endothelial progenitor cells. *Circ Res* 2003;93(10):980–9.
4. Hill JM, Zalos G, Halcox JP, Schenke WH, Waclawiw MA, Quyyumi AA, et al. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. *N Engl J Med* 2003;348(7):593–600.
5. Schmidt-Lucke C, Rossig L, Fichtlscherer S, Vasa M, Britten M, Kamper U, et al. Reduced number of circulating endothelial progenitor cells predicts future cardiovascular events: proof of concept for the clinical importance of endogenous vascular repair. *Circulation* 2005;111(22):2981–7.
6. Werner N, Kosiol S, Schiegl T, Ahlers P, Walenta K, Link A, et al. Circulating endothelial progenitor cells and cardiovascular outcomes. *N Engl J Med* 2005;353(10):999–1007.
7. Vasa M, Fichtlscherer S, Aicher A, Adler K, Urbich C, Martin H, et al. Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease. *Circ Res* 2001;89(1):E1–7.

8. Urbich C, Dimmeler S. Endothelial progenitor cells: characterization and role in vascular biology. *Circ Res* 2004;**95**(4):343–353.
9. Vasa M, Fichtlscherer S, Adler K, Aicher A, Martin H, Zeiher AM, et al. Increase in circulating endothelial progenitor cells by statin therapy in patients with stable coronary artery disease. *Circulation* 2001;**103**(24):2885–2890.
10. Stauffer BL, Hoetzer GL, Van Guilder GP, Smith DT, Desouza CA. Gender differences in endothelial tissue-type plasminogen activator release in middle-aged adults. *J Am Coll Cardiol* 2005;**45**(9):1547–1549.
11. Newby DE, McLeod AL, Uren NG, Flint L, Ludlam CA, Webb DJ, et al. Impaired coronary tissue plasminogen activator release is associated with coronary atherosclerosis and cigarette smoking: direct link between endothelial dysfunction and atherothrombosis. *Circulation* 2001;**103**(15):1936–1941.
12. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. *Circulation* 1998;**97**(18):1837–1847.
13. Sutherland DR, Anderson L, Keeney M, Nayar R, Chin-Yee I. The ISHAGE guidelines for CD34+ cell determination by flow cytometry. *International Society of Hematotherapy and Graft Engineering. J Hematother* 1996;**5**(3):213–226.
14. Kondo T, Hayashi M, Takeshita K, Numaguchi Y, Kobayashi K, Iino S, et al. Smoking cessation rapidly increases circulating progenitor cells in peripheral blood in chronic smokers. *Arterioscler Thromb Vasc Biol* 2004;**24**(8):1442–1447.
15. Distler JH, Allanore Y, Avouac J, Giacomelli R, Guiducci S, Moritz F, et al. EUSTAR statement and recommendations on endothelial precursor cells. *Ann Rheum Dis*; 2008.
16. Case J, Mead LE, Bessler WK, Prater D, White HA, Saadatzadeh MR, et al. Human CD34+ AC133+ VEGFR-2+ cells are not endothelial progenitor cells but distinct, primitive hematopoietic progenitors. *Exp Hematol* 2007;**35**(7):1109–1118.
17. Numaguchi Y, Sone T, Okumura K, Ishii M, Morita Y, Kubota R, et al. The impact of the capability of circulating progenitor cell to differentiate on myocardial salvage in patients with primary acute myocardial infarction. *Circulation* 2006;**114**(Suppl. 1):I114–I119.
18. Diller GP, van Eijl S, Okonko DO, Howard LS, Ali O, Thum T, et al. Circulating endothelial progenitor cells in patients with Eisenmenger syndrome and idiopathic pulmonary arterial hypertension. *Circulation* 2008;**117**(23):3020–3030.
19. Quyyumi AA, Hill JM. Circulating endothelial progenitor cells as novel biological determinants of vascular function and risk. *Can J Cardiol* 2004;**20**(Suppl. B):44B–48B.
20. Fadini GP, de Kreutzenberg S, Albiero M, Coracina A, Pagnin E, Baesso I, et al. Gender differences in endothelial progenitor cells and cardiovascular risk profile: the role of female estrogens. *Arterioscler Thromb Vasc Biol* 2008;**28**(5):997–1004.
21. Katz FE, Tindle R, Sutherland DR, Greaves MF. Identification of a membrane glycoprotein associated with haemopoietic progenitor cells. *Leuk Res* 1985;**9**(2):191–198.
22. Kocher AA, Schuster MD, Szabolcs MJ, Takuma S, Burkhoff D, Wang J, et al. Neovascularization of ischemic myocardium by human bone-marrow-derived angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and improves cardiac function. *Nat Med* 2001;**7**(4):430–436.
23. Kawamoto A, Iwasaki H, Kusano K, Murayama T, Oyama A, Silver M, et al. CD34-positive cells exhibit increased potency and safety for therapeutic neovascularization after myocardial infarction compared with total mononuclear cells. *Circulation* 2006;**114**(20):2163–2169.
24. Ingram DA, Caplice NM, Yoder MC. Unresolved questions, changing definitions, and novel paradigms for defining endothelial progenitor cells. *Blood* 2005;**106**(5):1525–1531.
25. Hristov M, Erl W, Weber PC. Endothelial progenitor cells: isolation and characterization. *Trends Cardiovasc Med* 2003;**13**(5):201–206.
26. Fadini GP, Coracina A, Baesso I, Agostini C, Tiengo A, Avogaro A, et al. Peripheral blood CD34+ KDR+ endothelial progenitor cells are determinants of subclinical atherosclerosis in a middle-aged general population. *Stroke* 2006;**37**(9):2277–2282.
27. Hoetzer GL, MacEaney OJ, Irmiger HM, Keith R, Van Guilder GP, Stauffer BL, et al. Gender differences in circulating endothelial progenitor cell colony-forming capacity and migratory activity in middle-aged adults. *Am J Cardiol* 2007;**99**(1):46–48.